Han X - Search Results

1

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Dai H, et al. Among authors: han x, han w. J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8. J Hematol Oncol. 2020. PMID: 32245502 Free PMC article. Clinical Trial.

2

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.

Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, Guo Y, Guo B, Ti D, Han X, Yang Q, Wu Z, Han W. Jia H, et al. Among authors: han x, han w. J Hematol Oncol. 2019 Jun 10;12(1):57. doi: 10.1186/s13045-019-0741-6. J Hematol Oncol. 2019. PMID: 31182121 Free PMC article.

3

Target selection for CAR-T therapy.

Wei J, Han X, Bo J, Han W. Wei J, et al. Among authors: han x, han w. J Hematol Oncol. 2019 Jun 20;12(1):62. doi: 10.1186/s13045-019-0758-x. J Hematol Oncol. 2019. PMID: 31221182 Free PMC article. Review.

4

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.

Han X, Wang Y, Wei J, Han W. Han X, et al. Among authors: han w. J Hematol Oncol. 2019 Nov 29;12(1):128. doi: 10.1186/s13045-019-0813-7. J Hematol Oncol. 2019. PMID: 31783889 Free PMC article. Review.

5

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Dai H, et al. Among authors: han x, han w. J Hematol Oncol. 2020 May 18;13(1):53. doi: 10.1186/s13045-020-00878-2. J Hematol Oncol. 2020. PMID: 32423426 Free PMC article.

6

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W. Tong C, et al. Among authors: han x, han w. Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. Blood. 2020. PMID: 32556247 Free PMC article. Clinical Trial.

7

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.

Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P. Dai H, et al. Among authors: han x. Oncoimmunology. 2020 Nov 25;9(1):1846926. doi: 10.1080/2162402X.2020.1846926. Oncoimmunology. 2020. PMID: 33312759 Free PMC article. Clinical Trial.

8

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.

Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Wang Y, et al. Among authors: han x, han w. Nat Commun. 2021 Jan 18;12(1):409. doi: 10.1038/s41467-020-20696-x. Nat Commun. 2021. PMID: 33462245 Free PMC article.

9

Chimeric antigen receptor modified T-cells for cancer treatment.

Han X, Wang Y, Han WD. Han X, et al. Among authors: han wd. Chronic Dis Transl Med. 2018 Sep 18;4(4):225-243. doi: 10.1016/j.cdtm.2018.08.002. eCollection 2018 Dec. Chronic Dis Transl Med. 2018. PMID: 30603741 Free PMC article.

10

Tissue factor in tumor microenvironment: a systematic review.

Han X, Guo B, Li Y, Zhu B. Han X, et al. J Hematol Oncol. 2014 Aug 1;7:54. doi: 10.1186/s13045-014-0054-8. J Hematol Oncol. 2014. PMID: 25084809 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19,273 results

Search Page